Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.